Avalo Therapeutics (AVTX) Receivables - Net (2016 - 2023)

Avalo Therapeutics (AVTX) has 8 years of Receivables - Net data on file, last reported at $38000.0 in Q2 2023.

• Quarterly Receivables - Net fell 95.78% year-over-year to $38000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $38000.0 (down 95.78% YoY) and the FY2021 annual result came in at $1.1 million, down 51.31% from the prior year.
• Receivables - Net fell to $38000.0 in Q2 2023, from $800000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $5.5 million in Q1 2019 to a low of $38000.0 in Q2 2023.
• A 5-year average of $1.9 million and a median of $1.6 million in 2020 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2019 — Receivables - Net jumped 3149.59% — and 2023, when it tumbled 95.78%.
• Tracing AVTX's Receivables - Net over 5 years: stood at $1.0 million in 2019, then soared by 117.34% to $2.2 million in 2020, then tumbled by 51.31% to $1.1 million in 2021, then retreated by 24.53% to $800000.0 in 2022, then slumped by 95.25% to $38000.0 in 2023.
• The last three Receivables - Net figures came in at $38000.0 (Q2 2023), $800000.0 (Q3 2022), and $900000.0 (Q2 2022), per Business Quant data.